Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells

Published:2020-02-01 Issue:5 Volume:38 Page:1292-1302
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Qu Feng,Gu Yue,Wang Qizhi,He Mingzhe,Zhou Fang,Sun Jianguo,Wang Guangji,Peng Ying^ORCID

Funder

the National Key New Drug Creation Special Program of China

the Drug Innovation Major Project

the National Natural Science Foundation of China

the Jiangsu Province Natural Science Project

Nanjing Medical Science and Technique Development Foundation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-020-00901-w.pdf

Reference40 articles.

1. Romero-Otero J, Garcia-Gomez B, Duarte-Ojeda JM, Rodriguez-Antolin A, Vilaseca A, Carlsson SV, Touijer KA (2016) Active surveillance for prostate cancer. International journal of urology : official journal of the Japanese Urological Association 23(3):211–218. https://doi.org/10.1111/iju.13016

2. Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzveig R, Maughan B, Agarwal N (2017) Incidence and characterization of Antiandrogen withdrawal syndrome after discontinuation of treatment with Enzalutamide in castration-resistant prostate Cancer. Clinical genitourinary cancer. https://doi.org/10.1016/j.clgc.2017.08.017

3. Bergerat JP, Ceraline J (2009) Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum Mutat 30(2):145–157. https://doi.org/10.1002/humu.20848

4. Brooke GN, Bevan CL (2009) The role of androgen receptor mutations in prostate cancer progression. Current genomics 10(1):18–25. https://doi.org/10.2174/138920209787581307

5. Koochekpour S (2010) Androgen receptor signaling and mutations in prostate cancer. Asian journal of andrology 12(5):639–657. https://doi.org/10.1038/aja.2010.89

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological targets of SGLT2 inhibition on prostate cancer mediated by circulating metabolites: a drug-target Mendelian randomization study;Frontiers in Pharmacology;2024-08-06

2. Scaffold Hopping of Pristimerin Provides Derivatives Containing a Privileged Quinoxaline Substructure as Potent Autophagy Inducers in Breast Cancer Cells;Journal of Natural Products;2024-08-06

3. Metabolomics and Proteomics in Prostate Cancer Research: Overview, Analytical Techniques, Data Analysis, and Recent Clinical Applications;International Journal of Molecular Sciences;2024-05-07

4. Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response;Proceedings of the National Academy of Sciences;2023-07-17

5. Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial;BMC Pharmacology and Toxicology;2023-06-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3